SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a parabolic rally driven by a low-float setup and intense short-squeeze dynamics that have captured the attention of retail traders. The community is actively debating the stock's long-term sustainability against its history of reverse splits and high borrowing costs, while many speculate about the potential for further explosive gains.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates the impact of recent delivery numbers and the launch of the new L80 model against a backdrop of ongoing short-seller activity. While some investors focus on strong year-over-year delivery growth and infrastructure expansion, others remain critical of the stock's performance and perceived manipulation by market makers.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing a high-volatility "sell the news" reaction despite delivering a record-breaking earnings beat and issuing bullish guidance that underscores sustained AI-driven demand. While the community is debating whether this dip offers a strategic buying opportunity or confirms a long-overdue valuation cooling after a historic year-long rally, many investors are focused on the company's aggressive share buyback plan as a potential defensive catalyst.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to the announcement of a multi-million dollar milestone payment from its partnership with Boehringer Ingelheim, which has triggered heightened trader interest ahead of an R&D Day presentation. Community sentiment is mixed, with some traders optimistic about the non-dilutive capital and autoimmune pipeline potential, while others remain cautious due to concerns over potential share dilution and a pending reverse stock split.

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

iSpecimen Inc. is attracting significant community attention due to its status as a low-float stock experiencing intense volatility, with retail investors closely monitoring for a potential short squeeze amid rumors of strategic acquisitions. Community sentiment is deeply polarized, with active debates centered on the company's long-term viability, upcoming delisting concerns, and the high-conviction participation of retail traders hoping to replicate past momentum spikes.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian shares are surging after delivering a strong quarterly earnings beat, fueling investor optimism that the enterprise software sector may be bottoming out. The community is actively debating if this performance signals a broader recovery for SaaS companies or if it remains a tactical bounce amid ongoing concerns over AI-driven disruption.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is seeing heightened community discussion as investors weigh the impact of new capital partnerships against broader sector volatility and bearish sentiment surrounding fintech. While some market participants anticipate a potential short squeeze, others remain cautious as the stock grapples with macroeconomic headwinds and lingering uncertainty regarding the company's performance in a high-rate environment.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is trending as traders closely monitor its role as a leveraged Bitcoin proxy, with community discussion currently polarized between optimism over institutional accumulation and concerns regarding structural dilution. Investors remain focused on how the company's treasury strategy and dividend structure will perform in relation to broader Bitcoin price volatility.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are closely monitoring escalating geopolitical tensions in the Strait of Hormuz and a shifting conflict status with Iran, which is driving significant volatility and concerns over energy supply stability. The community is actively debating whether current stock market highs are sustainable in the face of these rising oil prices, Fed policy uncertainty, and mixed earnings reports.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is drawing community attention as investors capitalize on an accumulation window, spurred by the launch of the ASI:Chain TestNet and anticipation surrounding autonomous AI agent development. Despite market volatility, sentiment remains bullish with many focusing on the project's long-term infrastructure potential and ongoing integrations with major tech and logistics partners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer (NYSE:PFE) Trading 1.8% Higher - Should You Buy?

Pfizer (NYSE:PFE) Trading Up 1.8% - What's Next...

The Vaccine Safety Signal The Media Still Won't Read

The Vaccine Safety Signal The Media Still Won't Read Authored by Dr. Joseph Fraiman via the Brownstone Institute, The serious-adverse-event signal found in the Pfizer and Moderna mRNA Covid-19...

Pfizer Just Scored a Win That Wall Street Can't Ignore

Key PointsPfizer persuaded three drugmakers to delay the production of generic Vyndamax...

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings

Pfizer sees mixed Q1 signals as growth in key drugs offsets COVID declines. Can pipeline strength and M&A bets support long-term upside?

World Investment Advisors Acquires 40,239 Shares of Pfizer Inc. $PFE

World Investment Advisors boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 11.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 397,952 shares of the biopharmaceutical company's stock afte...

Goldman Sachs resets Pfizer stock forecast

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and Goldman Sachs appears to be asking for more proof before getting more...

BMY's Q1 Earnings Top Estimates, Breyanzi, Camzyos Drive Sales

Bristol-Myers beats Q1 estimates as strong Growth Portfolio sales and Eliquis demand offset legacy drug declines.

Ahead of Pfizer (PFE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Eli Lilly (LLY) Beats Q1 Earnings and Revenue Estimates

Lilly (LLY) delivered earnings and revenue surprises of +21.06% and +12.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Pfizer reports Phase 3 data showing ELREXFIO improved progression-free survival versus standard therapy in multiple myeloma study.read more...

This account has been verified as an official PFE representative.

Verified Account

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.72	--	--	N/A
Q4 '25	$0.57	$0.66	16.43%	BEAT
Q3 '25	$0.63	$0.87	37.52%	BEAT
Q2 '25	$0.58	$0.78	34.34%	BEAT
Q1 '25	$0.67	$0.92	38.23%	BEAT

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest PFE News

PFEPfizer Inc